北京天坛生物制品股份有限公司 specializes in blood product manufacturing and biopharmaceuticals, focusing on innovations and enhancements in health services, including blood collection and plasma treatments. The company is described as engaged in rural revitalization and social welfare activities.

北京天坛生物制品股份有限公司

SSL by Default

HSTS

Apache

Apache 2.4

PHP 7

COVID-19

DigiCert SSL

OpenSSL

GeoTrust SSL

Duojia Feng

Zhenshan Wu

Beijing Public Companies With More Than $50M in Revenue

Beijing Companies

Asia-Pacific (APAC) Biotechnology Public Companies

Biotechnology Companies With More Than $10M in Revenue

Beijing Tiantan Biological Products Co., Ltd. (referred to as "Tiantan Biological Products") is engaged in vaccines, blood products, diagnostic products and other biological products, production and operation of enterprises, in 1998 by the Beijing Institute of Biological Products (formerly 1919 Northern Government Department established in the central epidemic prevention, is the cradle of Chinese biological products) launched listed on the Shanghai Stock Exchange, now the controlling shareholder is China National pharmaceutical Group Corporation. With the development of the company now has subsidiaries Changchun Chi-Biological Products Co., Ltd., a number of apheresis plasma companies. 

Tiantan Biological has 110 kinds of products, including hepatitis B vaccine, polio vaccine, MMR vaccine, Japanese encephalitis vaccine, influenza vaccine, varicella vaccine, human serum albumin, intravenous human immunoglobulin and other varieties, national immunization program vaccine is an important production base. 

Listed decades, the company accumulated dividends 477 million yuan, the total assets of the company, the main revenue, total profits have achieved more than 400% growth. Companies in 2006--2008 for three consecutive years won the "Golden Round Table Award for outstanding board of directors" award, won the 10th (2007) Chinese Listed Companies "Golden Bull Award shareholder returns hundred" and other awards.

Beijing

China

Asia

Beijing Tiantan Biological Products

A Chinese Covid-19 vaccine has proved effective, its maker says

For China, a Bridge Over the Adriatic Is a Road Into Europe

BRIEF-Beijing Tiantan Biological Products Says Its 2017 Net Profit Up

Antibody Technologies Market Share and Growth Factors Impact Analysis 2025

Global Blood Banking and Blood Products Industry

Human Vaccine Market in China 2018 Forecasts (Hib, Human Rabies, Varicella, Influenza) Research Reports

Global IVIG Industry Report 2014

United States

North America

Ukraine

Europe

HTML5

Apache Server

jQuery

F5 NGINX

Adobe Flash

DigiCert

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.

Beijing Tiantan Biological Products Co., Ltd.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:43 PM	ec993f43
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:43 PM	feaf01b5
crunchbase trigger	general	Nov 17, 2024 8:43 PM	22409bc7
crunchbase profile	general	Nov 17, 2024 9:04 PM	d62cb279
li profile	general	Nov 17, 2024 8:43 PM	33d141cc
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	389e7c1b
peers	general	Nov 17, 2024 8:43 PM	953cc44b
news basic	general	Nov 17, 2024 8:43 PM	47c96075
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

6001

COM:TIANTANBIO

北京天坛生物制品股份有限公司

Last Close

22.03

22/11 07:00

Market Cap

47.00B

Beta: -

Volume Today

20.09M

Avg: -